Emerging Cancer Therapeutics is a trinary hard cover periodical that is designed to provide an up-to-date evidence-based review of a dedicated emerging cancer therapy topic of interest to clinicians and scientists involved in the care of patients receiving cancer treatment. It will serve as both a reference and instructional tool for students, housestaff, fellows, practicing clinical oncologists, radiation oncologists, surgical oncologists, cancer biologists, and interdisciplinary colleagues throughout the oncology spectrum.
With contributions from nationally recognized experts representing the fields of dermatology, dermatologic surgery, surgical oncology, dermatopathology, and medical oncology, Melanoma includes chapters on prevention, changes in melanoma staging, the evolving role of established surgical therapies, single-agent specific V600E mutant inhibitors, target therapy for patients without BRAF mutations, new treatments for metastatic melanoma-including ipilimumab and vemurafenib-and more.
